Connect with us

Press Release

Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Published

on

–News Direct–

By Jeremy Golden, Benzinga

Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.

Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.

Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.

Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.

Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.

CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.

Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.

CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).

When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:

1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;

2) Favorable changes in the trajectory of tumor progression;

3) Decreased tumor size of target lesions in most patients; and

4) Reduced size of uninjected tumor lesions.

The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.

As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.

When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.

In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.

In the upcoming year, Candel plans to announce data readouts for the following:

1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;

2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;

3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.

Featured photo by National Cancer Institute on Unsplash.

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Aljanae Reynolds

+1 617-916-5445

areynolds@wheelhouselsa.com

Company Website

https://www.candeltx.com/

View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267

Candel Therapeutics

comtex tracking

COMTEX_453480918/2655/2024-06-07T08:28:02

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

DLMSPV LLC and Michael Hartnett Helping Global Investors Identify Quality Assets through DSLAI and DLMSPVAI Frameworks

Published

on

In the complex world of global finance, the ability to distinguish between noise and genuine opportunity has become the defining factor separating consistent success from uncertainty. As global markets evolve under the influence of AI, digitization, and capital redistribution, investors face an overwhelming array of data and decisions. DLM SPV LLC, under the strategic guidance of renowned analyst and educator Michael Hartnett, is pioneering a data-driven approach that simplifies this challenge — integrating artificial intelligence and behavioral modeling through its proprietary systems, DSLAI, DLMSPV, and DLMSPVAI.

The Modern Investor’s Dilemma

The financial markets of 2025 are unlike any in previous decades. Volatility has become a constant companion, inflationary cycles are unpredictable, and traditional valuation models often fail to capture the momentum behind emerging sectors. Investors are forced to adapt, searching for assets that combine stability, transparency, and long-term growth potential.

In this landscape, the question is no longer what to buy, but how to identify quality. The criteria for defining “high-quality assets” have evolved — it now encompasses not just performance, but also resilience, governance, and data-backed fundamentals.

Michael Hartnett, who has spent years studying global capital flows and behavioral finance, believes that technology can finally bridge the gap between complexity and clarity. “Investors are not struggling from a lack of data,” Hartnett explains. “They are struggling because there’s too much of it. The key is to filter information through intelligent systems that can recognize real value where others see only volatility.”

Introducing DSLAI and DLMSPVAI — Redefining Analytical Precision

At the core of DLM SPV LLC’s approach are DSLAI (Dynamic Smart Learning AI) and DLMSPVAI, two interconnected analytical engines that combine data modeling, sentiment analysis, and structural pattern verification.

DSLAI operates as a machine learning backbone that continuously studies correlations between macroeconomic indicators, corporate disclosures, and behavioral market signals. It is designed to understand not only what moves markets but why. By decoding hidden relationships between liquidity trends, risk tolerance, and capital rotation, DSLAI can flag potential opportunities long before they reach mainstream attention.

Complementing this is DLMSPVAI, an evolved model that applies predictive analytics to simulate multiple market scenarios. Rather than focusing on short-term price changes, DLMSPVAI measures sustainability — identifying assets capable of withstanding cyclical downturns and technological disruptions.

Together, the two systems represent DLM SPV’s philosophy: empowering investors through knowledge, not speculation.

The DLM SPV Framework: Where AI Meets Human Insight

Technology alone cannot define a good investment. While DSLAI and DLMSPVAI automate large-scale data processing, human interpretation remains critical. Michael Hartnett emphasizes that “data is only as good as the discipline guiding it.”

Under the DLMSPV (Dynamic Learning Market Smart Portfolio Validation) model, DLM SPV LLC combines algorithmic forecasting with human review. Analysts trained under the DLM framework evaluate data through multiple dimensions: sector relevance, liquidity depth, management quality, and regulatory transparency.

This hybrid approach ensures that the AI’s findings are grounded in real-world reasoning. It is not merely a matter of numbers but of narrative — understanding how global events, leadership decisions, and consumer sentiment collectively shape an asset’s trajectory.

Redefining What “Quality” Means in a Fragmented Market

According to Hartnett, the term “quality” has been misinterpreted for too long. “Investors often equate quality with brand recognition or market capitalization,” he notes. “But true quality is defined by adaptability — the ability of an asset or a company to generate consistent value across different economic cycles.”

Through DSLAI and DLMSPVAI, DLM SPV identifies these traits by analyzing the behavioral consistency of assets over time. For example:

How do institutional holdings shift during uncertainty?

How resilient are earnings against interest rate changes?

Does the underlying business model scale with technological transformation?

These questions go beyond price movements, capturing a deeper picture of structural strength.

The Role of AI in Democratizing Market Access

For decades, institutional investors held an advantage in accessing complex analytical tools and datasets. Retail and mid-level investors often relied on fragmented sources of information. DLM SPV LLC aims to close this gap by leveraging AI frameworks like DSLAI to create transparent analytical access for all investors — whether they are managing a personal portfolio or institutional capital.

Through its platform at https://dlmqy.com, DLM SPV integrates interactive dashboards and algorithmic insights that translate raw financial data into actionable intelligence. Users can visualize correlations, assess market health, and identify early signals of structural change.

This is not about predicting markets with absolute certainty — an impossible task — but about increasing the probability of success through better-informed decisions.

Michael Hartnett’s Philosophy: From Teaching to Empowering

Michael Hartnett’s contribution to DLM SPV extends beyond technical systems. A long-time educator and analyst, he believes that investment literacy is as important as access to capital.

“The most valuable asset is understanding,” he says. “Technology amplifies knowledge, but it cannot replace judgment. That’s why DLM SPV’s mission is not only to deliver tools but to cultivate decision-makers.”

To this end, the company has integrated education modules within its ecosystem — allowing users to learn how DSLAI and DLMSPVAI interpret data, rather than simply accepting recommendations. The goal is transparency: empowering investors to trust their reasoning as much as the algorithm.

The Rise of Data-Conscious Investing

The success of DLM SPV’s approach reflects a broader shift across the investment world. Traditional asset managers are embracing AI not as a novelty but as a necessity. As markets become more interconnected, the ability to process information at scale is essential.

DLM SPV’s innovation lies in how it applies AI to human behavior, not just numbers. By modeling collective decision patterns, DSLAI identifies when market sentiment diverges from fundamentals — often a precursor to correction or opportunity.

This perspective is especially valuable in the age of behavioral volatility, where sentiment, social trends, and algorithmic trading intersect.

Balancing Automation and Accountability

One of the recurring challenges in financial AI systems is accountability — ensuring that automated insights remain ethical, unbiased, and verifiable.

DLM SPV LLC has developed DLMSPVAI’s validation layer, which requires human confirmation for all AI-generated signals before portfolio action. This safeguards against overreliance on algorithmic bias and reinforces a culture of professional accountability.

Hartnett explains, “Technology should not replace trust — it should earn it. The best systems are those that make investors more aware, not more dependent.”

From Analysis to Action: Turning Knowledge into Portfolio Strength

Identifying a quality asset is only the beginning. What distinguishes DLM SPV’s framework is how it translates intelligence into structured portfolio validation.

Through the DLMSPV model, assets are evaluated not only for performance but for interconnectivity — how each position strengthens or diversifies the overall portfolio. The AI’s ability to detect unseen correlations allows investors to reduce exposure to systemic risk while optimizing growth potential.

This methodology has gained attention among institutional advisors seeking to merge AI analytics with responsible portfolio construction.

Looking Ahead: Building a Smarter Financial Future

As global markets transition into an era dominated by digital assets, tokenization, and real-world asset integration, DLM SPV LLC is positioning itself as a thought leader in intelligent asset discovery.

The company’s vision extends beyond short-term market relevance. Its goal is to redefine how investors interact with information — transforming data into comprehension, and comprehension into confidence.

Michael Hartnett summarizes this mission succinctly:

“The future of investing is not about prediction; it’s about perception. Those who understand the structure of change will always find opportunity within it.”

Conclusion

In a world where data is abundant but clarity is rare, DLM SPV LLC and Michael Hartnett are offering a bridge — connecting technology, transparency, and education. Through systems like DSLAI, DLMSPV, and DLMSPVAI, the company is building more than analytical tools; it is cultivating a philosophy of informed, intelligent investing.

Investors seeking to learn more about DLM SPV’s framework or explore its analytical systems can visit https://dlmqy.com or contact services@dlmqys.vip for further information.

As financial markets continue to evolve, one truth remains: the most powerful investment is not in assets themselves, but in the knowledge that helps define them.

Media Contact

Organization: DLM SPV LLC

Contact Person: Michael Hartnett

Website: https://dlmqy.com/

Email:
services@dlmqys.vip

Country:Armenia

Release id:35056

The post DLMSPV LLC and Michael Hartnett Helping Global Investors Identify Quality Assets through DSLAI and DLMSPVAI Frameworks appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Forex Expo Dubai Wins Guinness World Records™ with 20,021 Visitors

Published

on

Dubai, UAE, 8th October 2025, ZEX PR WIRE, By winning the Guinness World Records™ for “Largest attendance at a Forex Event” & “Most Exhibitors at a Forex Event”, the 8th edition of Forex Expo Dubai this year is announced as the world’s largest event in forex & online trading industry.

The historical event, Forex Expo took place in Dubai World Trade Center (DWTC) on 6-7 October 2025 with 262 Exhibiting companies and 147 Industry Experts as speaker from over 100 Countries making the world’s largest exhibition and conference in online trading industry.

The record was achieved during Forex Expo Dubai, as footfall reached 20,021 visitors that comprises of 16,994 online traders/investors, 671 IBs/Affiliates  and 2,356 business professionals, reinforcing Dubai’s position as the financial powerhouse of the Middle East.

Early this Monday, Dubai Police noted traffic congestion around the Dubai World Trade Centre (DWTC) as large crowds arrived for Forex Expo and two other concurrent events, highlighting the venue’s growing role as a hub for international gatherings.

Niyaz Mohamed from Forex Expo Team added “This achievement goes beyond numbers — it reflects Forex Expo Dubai’s position as a global platform for innovation and finance. We’re honoured to set new benchmarks for the forex industry.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Vitals Vault Brings $4,500 Longevity Clinic Testing to the Public for Just $399

Published

on

100+ biomarkers, AI-powered insights, and early detection are now accessible to everyone.

Seattle, WA, USA– Vitals Vault, a next-generation health optimization platform, is transforming how individuals take control of their health. By offering access to over 100 precision biomarker tests, AI-driven insights, and clinician-reviewed reports, Vitals Vault is bridging the gap between expensive longevity clinics and the limited scope of traditional annual physicals.

Accessible Pricing with Launch Special

Individually, these tests cost over $1,700 if purchased separately. The full Vitals Vault comprehensive panel regularly retails for $599, already a fraction of the price of longevity clinics that charge $4,000 -$5,000. For its limited launch, Vitals Vault is making this same full-body health scan available for just $399 – bringing advanced longevity testing within reach for everyone.

The Number That Matters More Than Your Birthday

Beyond testing for disease risk, Vitals Vault measures how fast your body is actually aging. Using PhenoAge, an advanced algorithm built from key blood markers, the platform calculates your biological age – a true reflection of cellular health, resilience, and longevity potential. Unlike your birthdate, this measure shows whether you’re aging faster or slower than expected. Armed with this insight, individuals can take targeted, science-based steps proven to slow – and in some cases reverse – the pace of aging.

A New Era in Preventive Health

For decades, the standard medical model has focused on detecting sickness rather than preventing it. Annual physicals typically measure only 12–20 markers, leaving fatigue, hidden inflammation, and silent heart risk unnoticed until it’s too late.

Meanwhile, longevity clinics charge as much as $4,500 for advanced testing, placing optimal health out of reach for most people.

Vitals Vault challenges this system by making comprehensive testing and actionable health optimization accessible and affordable. With CLIA-certified labs, HIPAA-compliant data protection, and HSA/FSA eligibility, the platform delivers the same scientific rigor as elite clinics at a fraction of the cost.

What’s Included: 112+ Biomarkers That Go Far Beyond a Physical

Instead of the 12–20 basic labs typically offered at a doctor’s office, Vitals Vault provides a complete map of health with over 100+ tests across every major system. 

Some of the most critical include:

  • ApoB – The most powerful predictor of heart attack and stroke risk, yet rarely included in standard physicals.
  • Lipoprotein(a) – A hidden genetic risk factor most doctors never check, strongly linked to early heart attacks and strokes—even when cholesterol appears normal.
  • hs-CRP – A key inflammation marker not only driving silent cardiovascular disease, but also linked to accelerated biological aging and predicting future risk of heart attack years before symptoms appear.
  • Homocysteine – Elevated levels are linked not only to cognitive decline, stroke, and Alzheimer’s, but also to accelerated brain shrinkage—studies show lowering homocysteine with B-vitamins can slow brain atrophy by over 30% and preserve memory.
  • Advanced cholesterol & triglycerides – Go beyond ‘total cholesterol’ to reveal hidden particle patterns and lipid risks that standard panels miss.
  • Fasting insulin + HOMA-IR – Detect hidden insulin resistance years before glucose or A1C changes, offering an early warning for diabetes and metabolic disease.
  • Hemoglobin A1C – The gold standard for tracking long-term blood sugar control and uncovering hidden diabetes risk.
  • Full thyroid panel (TSH, Free T4, Free T3, Reverse T3, antibodies) – The most comprehensive thyroid check – revealing hidden imbalances that drive fatigue, stubborn weight gain, mood shifts, and hair loss that a standard TSH test alone often misses.
  • Ferritin & Iron – Reveal hidden anemia or iron overload—two underdiagnosed causes of constant exhaustion, brain fog, and poor performance.
  • Vitamin D, B12, Folate – Essential nutrient trio uncovering deficiencies that quietly drive fatigue, low mood, and weakened immunity.
  • Testosterone (free & total) – The master vitality hormone influencing energy, strength, mood, drive, and libido in both men and women – often overlooked outside men’s health.
  • Estradiol, Progesterone, FSH, LH – Core reproductive hormones regulating fertility, hormonal balance, mood, and life-stage transitions in both sexes, not just women.
  • Cortisol & DHEA-S – stress and resilience markers influencing sleep, recovery, and aging.
  • Liver enzymes (ALT, AST, GGT) – detect alcohol, medication, or diet-related strain.
  • Kidney markers (Creatinine, eGFR, Albumin/Creatinine Ratio) – uncover early kidney warning signs most doctors miss.

This depth of testing is designed to uncover imbalances years before they manifest as disease, empowering users to intervene early and live longer, healthier lives.

Personalized AI-Driven Health Reports

Every Vitals Vault client receives more than just raw lab data. Results are reviewed by advanced AI systems that compare biomarkers against optimal, not just “normal”, ranges. The platform delivers a personalized Functional Health Report that includes:

  • Food and supplement guidance tailored to biomarker results
  • Lifestyle recommendations for sleep, stress, and exercise
  • Urgent result flagging for immediate attention
  • A biological age (PhenoAge) calculation to measure true aging beyond the calendar

Health History Integration

Vitals Vault also empowers clients to upload past lab reports from other providers, creating a continuous health timeline. Instead of treating every test as an isolated snapshot, the platform stitches data together – revealing long-term trends, hidden patterns, and whether interventions are truly working. This longitudinal view, once only available at elite concierge clinics, is now accessible to everyone. Clients can securely track their progress, spot subtle changes early, and share evolving insights with their physicians.

Trusted, Affordable, and Transparent

Vitals Vault operates with a one-time $399 purchase; no subscriptions, no hidden fees, and no automatic renewals. Customers schedule their tests at one of 2,000+ Quest Diagnostics locations nationwide, receive results within 7 days, and gain access to insights typically reserved for the wealthy.

The company also offers a 60-day money-back guarantee, underscoring its confidence in providing measurable value.

Why Vitals Vault Matters Now

With 74% of adults reporting exhaustion and nearly all lacking clarity on the cause, Vitals Vault positions itself as the clear alternative to “bare minimum” healthcare. Instead of waiting years for conditions like pre-diabetes or hormone imbalances to surface, individuals can now identify risks early, act on them, and reclaim control of their health journey.

For more information, visit www.vitalsvault.com.

About Vitals Vault

Vitals Vault, Inc. is a Seattle-based health optimization company committed to making comprehensive, science-driven health insights accessible to everyone. Through partnerships with leading labs and the integration of AI technology, Vitals Vault delivers precision biomarker analysis, personalized action plans, and unparalleled value. The platform empowers individuals to take charge of their health, longevity, and performance, without the inflated costs of concierge medicine.

For updates follow Vitals Vault on LinkedIn: https://www.linkedin.com/company/vitals-vault/

Media Contact

Company Name: Vitals Vault, Inc.

Contact Person: Media Relations

Email: team@vitalsvault.com

Website: https://www.vitalsvault.com/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST